Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

NCT02616848 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

1

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Everolimus
DRUG: Eribulin

Sponsor

Istituti Ospitalieri di Cremona